Dragon Life Science Holdings Group, Inc.
NOHO · OTC
5/31/2023 | 2/28/2023 | 2/28/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $0 | $0 |
| % Growth | 6.1% | – | – | – |
| Cost of Goods Sold | $2 | $3 | $0 | $0 |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | 1.4% | -65.4% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $137 | $118 | $53 | $54 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $137 | $118 | $53 | $54 |
| Operating Income | -$137 | -$119 | -$53 | -$54 |
| % Margin | -7,481.4% | -6,879.5% | – | – |
| Other Income/Exp. Net | -$136 | $68 | $1,401 | $13 |
| Pre-Tax Income | -$273 | -$51 | $1,348 | -$41 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$273 | -$51 | $1,348 | -$41 |
| % Margin | -14,881.5% | -2,962.1% | – | – |
| EPS | -0 | -0 | 0 | -0 |
| % Growth | -432.9% | -102.6% | 3,317.9% | – |
| EPS Diluted | -0 | -0 | 0 | -0 |
| Weighted Avg Shares Out | 20,040,080 | 20,040,080 | 13,754,767 | 13,254,767 |
| Weighted Avg Shares Out Dil | 20,040,080 | 20,040,080 | 13,754,767 | 13,254,767 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $36 | $44 | $220 | $0 |
| Depreciation & Amortization | -$40 | $122 | $0 | $0 |
| EBITDA | -$237 | $115 | $1,568 | -$41 |
| % Margin | -12,899.6% | 6,670.4% | – | – |